In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025. On conclusion of the inspection, a Form-483 was issued with 6 observations. 'Observations are largely around improvement of procedures and practices and not related to data integrity. The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,' Piramal Pharma said in a statement. Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC). Powered by Capital Market - Live

Profit before tax stood at Rs 66.80 crore in the December 2024 quarter, registering a growth of 245.04% on YoY basis. During the quarter, EBITDA grew 6% YoY to Rs 350 crore and EBITDA margin improved to 16% as against 17% posted in Q3 FY24. On nine-month basis, the firm's reported consolidated net loss of Rs 62.37 crore in 9M FY25 as against net loss of Rs 83.45 crore in 9M FY24. Revenue from operations grew 13.85% YoY to Rs 6,397.11 crore during the nine period ended on 31 December 2024, primarily driven by high-teen growth in the CDMO business. EBITDA grew by 20% YoY to Rs 977 crore for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix. The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 3,659 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 1,928 crore (up 8% YoY) and India consumer healthcare (ICH) came in at Rs 819 crore (up 10% YoY) during the period under review. Nandini Piramal, chairperson of Piramal Pharma, said, 'FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth. The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip added 1.67% to currently trade at Rs 222.60 on the BSE. Powered by Capital Market - Live

Net profit of Piramal Pharma declined 63.60% to Rs 3.68 crore in the quarter ended December 2024 as against Rs 10.11 crore during the previous quarter ended December 2023. Sales rose 12.54% to Rs 2204.22 crore in the quarter ended December 2024 as against Rs 1958.57 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2204.221958.57 13 OPM %15.3213.70 - PBDT263.61237.95 11 PBT66.8051.63 29 NP3.6810.11 -64 Powered by Capital Market - Live

Chlorpromazine Hydrochloride Injection is a medicine used to treat various disorders such as schizophrenia and other psychoses like paranoia (delusions and feeling extremely worried or nervous), mania (overactive behavior), anxiety, agitation, and dangerously impulsive behavior. The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC had launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products. Peter DeYoung, chief executive officer, Piramal Global Pharma, said: 'We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing US portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The pharmaceutical company's consolidated net profit surged to Rs 22.59 crore in the quarter ended September 2024 as against Rs 5.02 crore during the previous quarter ended September 2023. Sales increased by 17.28% to Rs 2,241.75 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.95% to currently trade at Rs 244.95 on the BSE. Powered by Capital Market - Live

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live

Just Dial Ltd, Biocon Ltd, Vedant Fashions Ltd, Aditya Birla Capital Ltd are among the other stocks to see a surge in volumes on NSE today, 13 January 2025.Piramal Pharma Ltd registered volume of 286.28 lakh shares by 14:14 IST on NSE, a 6.62 fold spurt over two-week average daily volume of 43.22 lakh shares. The stock rose 5.85% to Rs.234.20. Volumes stood at 100.03 lakh shares in the last session.Just Dial Ltd notched up volume of 17.92 lakh shares by 14:14 IST on NSE, a 4.99 fold spurt over two-week average daily volume of 3.60 lakh shares. The stock slipped 8.39% to Rs.948.30. Volumes stood at 3.79 lakh shares in the last session.Biocon Ltd clocked volume of 201.5 lakh shares by 14:14 IST on NSE, a 4.98 times surge over two-week average daily volume of 40.46 lakh shares. The stock gained 0.83% to Rs.363.95. Volumes stood at 22.24 lakh shares in the last session.Vedant Fashions Ltd clocked volume of 6.78 lakh shares by 14:14 IST on NSE, a 4.92 times surge over two-week average daily volume of 1.38 lakh shares. The stock lost 1.24% to Rs.1,166.05. Volumes stood at 1.99 lakh shares in the last session.Aditya Birla Capital Ltd notched up volume of 127.7 lakh shares by 14:14 IST on NSE, a 4.8 fold spurt over two-week average daily volume of 26.63 lakh shares. The stock rose 1.41% to Rs.170.00. Volumes stood at 37.51 lakh shares in the last session.Powered by Capital Market - Live

The firm stated that consequent to Ponugoti's appointment, Sarosh Shetty ceases to be interim CEO of ICH. Sai Ramana Ponugoti brings over 20 years of diverse and exemplary leadership experience, gained through his tenure at Procter Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The pharmaceutical company's consolidated net profit zoomed 350% to Rs 22.59 crore in Q2 FY25 as against Rs 5.02 crore posted in Q2 FY24. Revenue from operations grew by 17.28% YoY to Rs 2,241.75 crore during the quarter. Powered by Capital Market - Live

Revenue from operations grew by 17.28% year on year (YoY) to Rs 2,241.75 crore during the quarter, primarily driven by robust growth in CDMO business. The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 1,324 crore (up 24% YoY), complex hospital generics (CHG) stood at Rs 643 crore (up 9% YoY) and India consumer healthcare (ICH) came in at Rs 277 crore (up 8% YoY) during the period under review. The drug maker's profit before tax soared 203.64% to Rs 120.12 crore in September 2024 quarter from Rs 39.56 crore posted in same quarter a year ago. EBITDA grew 28% YoY to Rs 403 crore with EBITDA margin of 18%, a YoY improvement of over 150 bps, driven by operating leverage, cost optimization initiatives and superior revenue mix. Nandini Piramal, chairperson of Piramal Pharma, said, 'We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced a US$80Mn expansion plan at our Lexington facility which is expected to get complete by end FY27. In our CHG business, we are witnessing steady volume growth in inhalation anesthesia products in the US and Emerging Markets. In our ICH business, we continue to see a robust growth in our power brands and e-commerce sales. During the quarter, we released our Sustainability Report for FY24 under the theme, 'Building Resilience for a Sustainable Tomorrow', highlighting our progress on the sustainability initiatives. Over the long term, we remain committed to achieving our financial goals of $2 billion revenue with 25% EBITDA margin and 1x net debt / EBITDA by FY30.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip hit an all time high of Rs 249.60 in today's intraday session.Powered by Capital Market - Live

The headline equity benchmarks traded with minor gains in morning trade. The Nifty traded above the 24,400 level. PSU Bank shares extended gains for the second consecutive trading session. Trading could be volatile due to weekly F&O series expiry today. At 10:30 IST, the barometer index, the S&P BSE Sensex, added 21.40 points or 0.03% to 80,103.38. The Nifty 50 index rose 3.05 points or 0.01% to 24,438.55. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.40% and the S&P BSE Small-Cap index added 0.27%. The market breadth was positive. On the BSE, 1,836 shares rose and 1,677 shares fell. A total of 159 shares were unchanged. Result today: ITC (down 0.97%), NTPC (up 0.67%), IndusInd Bank (down 0.26%), Radico khaitan (up 1.75%), United Breweries (down 1.37%), Aarti Drugs (down 0.38%), JSW Energy (down 0.66%), ACC (up 1.13%), Apcotex Industries (up 1.68%), Adani Total Gas (up 1.83%), Adani Wilmar (up 0.34%), Bikaji Foods International (up 0.53%), Castrol India (down 1.37%), Chalet Hotels (up 2.74%), CIE Automotive India (up 0.45%), Colgate-Palmolive (INDIA) (down 1.05%), CSB Bank (up 0.69%), Cyient (up 2.87%), DCB Bank (down 0.85%), Dixon Technologies (India) (up 0.74%), Finolex Industries (down 0.10%), Glenmark Life Sciences (down 1.01%), GMR Airports Infrastructure (up 1.40%), Go Digit General Insurance (down 0.37%), Godrej Consumer Products (down 1.10%), Home First Finance Company (down 0.35%) and Strides Pharma Science (up 1.05%) will declare their result later today. Buzzing Index: The Nifty PSU Bank index gained 1.08% to 6,421. The index rallied 1.53% in two consecutive trading sessions. UCO Bank (up 1.36%), Punjab National Bank (up 0.59%), Central Bank of India (up 0.42%), Canara Bank (up 0.41%), State Bank of India (up 0.38%), Bank of Baroda (up 0.35%), Indian Bank (up 0.29%), Punjab & Sind Bank (up 0.06%) advanced. On the other hand, Indian Overseas Bank (down 0.84%), Union Bank of India (down 0.58%) and Bank of Maharashtra (down 0.54%) edged lower. Stocks in Spotlight: Piramal Pharma surged 10.24% after the company's consolidated net profit surged 360% to Rs 23 crore during the quarter as compared with Rs 5 crore posted in corresponding quarter last year. Revenue increased 17% YoY to Rs 2,242 crore in Q2 FY25. Birlasoft slipped 3.71% after the company's consolidated net profit declined 14.66% to Rs 128 crore during the quarter as compared with Rs 150 crore in Q1 FY25. Revenue increased 3.08% QoQ to Rs 1,368 crore during the quarter. United Spirits shed 0.11%. The company's consolidated net profit fell 1.76% to Rs 335 crore during the quarter as compared with Rs 341 crore in Q2 FY24. Revenue (excluding excise duty) fell 0.77% to Rs 2,843 in Q2 FY25 as compared with Rs 2,865 crore in Q2 FY24. Powered by Capital Market - Live

Net profit of Piramal Pharma rose 350.00% to Rs 22.59 crore in the quarter ended September 2024 as against Rs 5.02 crore during the previous quarter ended September 2023. Sales rose 17.28% to Rs 2241.75 crore in the quarter ended September 2024 as against Rs 1911.38 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2241.751911.38 17 OPM %15.2413.90 - PBDT312.34224.07 39 PBT120.1239.56 204 NP22.595.02 350 Powered by Capital Market - Live